Key Takeaways From ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance
ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target
HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $18
Buy Rating Affirmed for ADMA Biologics Amid Strong Financial Performance and Promising R&D Prospects
ADMA Biologics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $15
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating
Mizuho Bank: Maintains the ADMA Biologics (ADMA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $10.00 to $12.00.
ADMA Biologics Analyst Ratings
Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $12
Strong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA Biologics
HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Raises Price Target to $7.5